Evaluating supervised haart in late-stage HIV among drug users: A preliminary report
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To examine response to highly active antiretroviral therapy (HAART) among a sample of treatment-experienced patients in the late stage of human immunodeficiency virus (HIV) infection in residential health care facilities (RHCFs) in New York City facilities designated for HIV/AIDS (acquired immunodeficiency syndrome) when access and adherence are maximized.
Medical record review of 111 patients.
Demographics were mean age 42 years; 58% male; 60% African-American; 31% Hispanic; 57% injection drug users (IDUs); 23% with history of dementia; 52% hepatitis C virus (HCV) antibody seropositive; 80% on HAART, of whom 18% had lipodystrophy. Of 88 patients on HAART, 52% had a decreased viral load (>1/2log) versus 13% of 23 not on HAART (P<.05); a>1/2log viral load increase was seen in 8% and 35%, respectively (P<.05). Those with viral load increase were more likely than those with stable/decreased viral load to be IDUs (71% vs. 64%) and to have HCV seropositivity (86% vs. 53%), even with similar initial CD4+ cell count, viral load, and follow-up time.
In a predominantly minority IDU population who are treatment experienced, 50% of the patients successfully responded to treatment with supervised therapy. The RHCFs in New York City provide a unique opportunity to examine further factors associated with response to HAART in an environment in which medication administration and adherence are maximized and monitored carefully.
- Centers for Disease Control: estimated incidence of AIDS and deaths of person with AIDS, adjusted for delays in reporting, by quarter-year of diagnosis/death. United States. January 1985–June 1997.HIV/AIDS Surveill Rep. 1997;9:1–44.
- Centers for Disease Control and Prevention. Update: trends in AIDS incidence, deaths and prevalence—United States, 1996.MMWR Morb Mortal Wkly Rep. 1997;46:165–173.
- Montaner JSG, Reiss P, Cooper D, et al. for the INCAS Study Group. A randomized, double-blind trial comparing combination of nevaripine, didanosine, and zidovudine for HIV-infected patients.JAMA. 1998;279:930–937. CrossRef
- Bangsberg D, Tulsky JP, Heicht RM, Moses AR. Protease inhibitors in the homeless.JAMA. 1997;278:63–65. CrossRef
- Centers for Disease Control and Prevention. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.JAMA. 1993;269(10):2492.
- Hoffman RA, Kung PC, Hansen WP, Goldstein G. Simple and rapid measurement of human T-lymphocytes and their subclasses in peripheral blood.Proc Natl Acad Sci USA. 1980;77:4914–4917.
- Giorgi JV, Cheng HL, Margolick JB, et al. Quality control in the flow cytometric measurement of T-lymphocyte subsets: the Multicenter AIDS Cohort experience.Clin Immunopathol. 1990;55:173–186.
- Galai N, Vlahov D, Margolick JB, Graham N, Muñoz A. Changes in markers of disease progression in HIV-1 seroconverters: a comparison between cohorts of injecting drug users and homosexual men.J Acquir Immune Defic Syndr. 1995;8:66–74.
- Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection.J Clin Microbiol. 1994;32:292–300.
- Collier CA, Coombs RW, Schoenfeld DA, et al. for the AIDS Clinical Trial Group. Treatment of human immunodeficiency virus infection with saquinavir, zidivudine and zalcitabine.N Engl J Med. 1996;334:1011–1017. CrossRef
- Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.N Engl J Med. 1997;337:734–739. CrossRef
- Hammer SM, Squires KE, Hughes MD, et al. for the AIDS Clinical Trial Group 320 Study Team. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4+ cell counts of 200 per cubic millimeter or less.N Engl J Med. 1997;337:725–733. CrossRef
- Cameron DW, Heath-Chiozzi M, Cohen C, et al. for the Advanced HIV Disease Ritonavir Study Group. Randomized placebo-controlled trial of ritanovir in advanced HIV-1 disease.Lancet. 1998;351:543–549. CrossRef
- Piketty C, Castiel P, Belec L, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease.AIDS. 1998;12:745–750. CrossRef
- Casado JL, Perez-Elías MJ, Antela A, et al. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients.AIDS. 1998;12:F131-F135.
- d'Arminio Montforte A, Testa L, Adorni F, et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-infection.AIDS. 1998;12:1631–1637.
- Mellors J. Combination protease inhibitor therapy. Session 84: update on antiretroviral therapy.Fourth Conference on Retroviruses and Opportunistic Infections; January 22–26, 1997; Washington, DC.
- Deeks S, Beatty G, Cohen PT, Grant R, Volberding P. Viral load and CD4+ T cell changes in patients failing potent protease inhibitor therapy [abstract].Fifth Conference on Retroviruses and Opportunistic Infections; February 1–5, 1998; Chicago, IL.
- Burger DM, Meenhorst PL, ten Napel CHH, et al. Pharmacokinetic variability of zidovudine in HIV-infected individuals: subgroup analysis and drug interactions.AIDS. 1994;8:1683–1689.
- Schwartz EL, Brechbühl A-B, Kahl P, Miller MA, Selwyn PA, Friedland GH. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug—using patients with HIV infection.J Acquir Immune Defic Syndr. 1992;5:619–626.
- McCance-Katz EF, Rainey P, Jatlow P, Friedland G. Methadone effects on zidovudine disposition (AIDS Clinical Trails Group 262).J Acquir Immune Defic Syndr. 1998;18:435–443.
- Santolamazza M, Lelli V, Santollamazza M, et al. Evaluation of effectiveness of antiretroviral therapy in three groups of HIV+drug addicted patients [abstract].Int Conf AIDS. 1998;12:1159. Abstract 60868.
- Veal GJ, Back DJ. Metabolism of zidovudine.Rev Gen Pharmacol. 1995;26:1469–1475.
- D'Offizi G, Campitelli G, Urso R, et al. Methadone and protease inhibitors in HIV-infected drug users [abstract].Int Conf AIDS. 1998;12:782. Abstract 41202.
- Flepp M, Nigg C, Kuhn F, et al. Nelfinaivr, didanosine and stavudine in HIV-infected drug users enrolled in opiate substitution programs at four outpatient clinic—the Zurich Prometheus Study [abstract].Int Conf AIDS. 1998;12:829. Abstract 42281.
- Melvin DC, Lee JK, Belsey E, et al. The impact of co-infection with hepatitis C virus and human immunodeficiency virus on the tolerability of highly active antiretroviral therapy [abstract]. In:Program and Abstracts of the International Conference on the Discovery and Clinical Development of Antiretroviral Therapies; St. Thomas, West Indies; Antiviral Therapy 1998;3(suppl 5):56–57. Abstract 60.
- Voorman RL, Maio SM, Hauer MJ, Sanders PE, Payne NA, Ackland MJ. Metabolism of delvaridine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYPD2D6 and CYP3A.Drug Metab Dispos 1998;26:631–639.
- Koudriakova T, Iatsimirskaia E, Utkin I, et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.Drug Metab Dispos. 1998;26:552–561.
- Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4.Drug Metab Dispos. 1997;25:256–266.
- Payan C, Riou M, Dummont B, et al. Hepatitis B reactivation after triple combination therapy and higher immunological response for HIV-1 infection [abstract].Abstr Gen Meet Am Soc Microbiol. May 17–21, 1998;98:488. Abstract S-4.
- Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V, Munoz F, Gonzalez-Lahoz J. Hepatotoxicity after introduction of highly active antiretroviral therapy (HAART) [abstract].Int Conf AIDS. 1998;12:70. Abstract 12288.
- Vento S, Garofano T, Renzini C, Casali F, Ferraro T, Concia E. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy.AIDS. 1998;12:116–117.
- Jeurissen FJ, Schneider MM, Borleffs JC. Is the combination of hepatitis and indinavir potentially dangerous? [Letter].AIDS. 1998;12:441–442.
- Brau N, Leaf HL, Wieczorek RL, Margolis DM. Severe hepatitis in three AIDS patients treated with indinavir [letter; comment].Lancet. 1997;349:924–925. CrossRef
- Arribas JR, Ibanez C, Ruiz-Antoran B, et al. Acute hepatitis in HIV-infected patients during ritonavir treatment [letter].AIDS. 1998;12:1722–1724.
- Coutinho RA. HIV and hepatitis C among injecting drug users. Success in preventing HIV has not been mirrored for hepatitis C.BMJ. 1998;317:424–425.
- Evaluating supervised haart in late-stage HIV among drug users: A preliminary report
Journal of Urban Health
Volume 76, Issue 4 , pp 468-480
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Advanced HIV
- Hepatitis C Seropositivity
- Residential Health Care Facilities
- Substance Abuse
- Viral Load
- Author Affiliations
- 1. Office of Special Populations/Center for Urban Epidemiologic Studies, New York Academy of Medicine, Room 443, 1216 Fifth Avenue, 10029, New York, NY
- 2. Bronx-Lebanon Special Care Center, Bronx-Lebanon, USA
- 3. AIDS Institute, New York State Department of Health, New York, USA